OWL vs IMVT Comparison

Blue Owl Capital is one of the world's largest alternative-asset managers, $307.4 billion in total managed assets, including $187.7 billion in fee-earning AUM, at the end of 2025. The company has three core business segments: global private equity, (with $69.1 billion in total AUM and $39.5 billion in fee-earning AUM), private credit ($157.7 billion/$99.5 billion), and real estate/real assets ($80.6 billion/$48.7 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). Blue Owl operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.